23andMe Inc. is a consumer genetics and research company. It involved in discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory and cardiovascular diseases, in addition to other therapeutic areas. 23andMe Inc., formerly known as VG Acquisition Corp., is headquartered in Sunnyvale, CA.
| Revenue (Most Recent Fiscal Year) | $189.90M |
| Net Income (Most Recent Fiscal Year) | $-280.89M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.56 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -116.70% |
| Net Margin (Trailing 12 Months) | -130.25% |
| Return on Equity (Trailing 12 Months) | -827.24% |
| Return on Assets (Trailing 12 Months) | -87.31% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.81 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.69 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 5.01 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.97 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 27.54M |
| Free Float | 20.29M |
| Market Capitalization | $98.60M |
| Average Volume (Last 20 Days) | 0.13M |
| Beta (Past 60 Months) | 2.12 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 26.32% |
| Percentage Held By Institutions (Latest 13F Reports) | 36.10% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |